Capecitabine in pretreated metastatic cholangiocarcinoma. A case report and review of the literature.

• Abstract: Cholangiocarcinoma is one of the most aggressive malignancies. Patients with advanced or metastatic disease have a particularly dismal prognosis. The role of chemotherapy remains a matter of debate. A number of recent trials have shown that capecitabine in combination with other agents seems to be active as first-line treatment in advanced biliary cancer. Clinical data regarding the activity of capecitabine in pretreated patients are limited. In this report we describe a patient with previously treated, metastatic cholangiocarcinoma who developed stabilization of the disease for 7 months following chemotherapy with capecitabine. The patient had previously received 2 lines of chemotherapy. Capecitabine was tolerated fairly well without serious adverse events. We consider this observation to be important given the absence of active, non-surgical treatments in unresectable tumors.
• Authors: A K Koutras, G Talampuka, N Pagoni, K C Thomopoulos, G Kalliolias, C Kalogeropoulou, H P Kalofonos (Affiliation: Division of Oncology, Department of Medicine, University Hospital, Patras Medical School, Rion, Greece. angkoutr at otenet.gr)
• Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology (J BUON) 2007 Apr-Jun Vol. 12 Issue 2 Pg. 281-3 ISSN: 1107-0625 [Print] Greece
• PMID: 17600885 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Antimetabolites, Antineoplastic
• Carcinoembryonic Antigen
• capecitabine
• Fluorouracil
• Deoxycytidine

Topics

• Antimetabolites, Antineoplastic (administration & dosage, therapeutic use)
• Bile Duct Neoplasms (drug therapy)
• Carcinoembryonic Antigen (blood)
• Cholangiocarcinoma (drug therapy, secondary)
• Deoxycytidine (administration & dosage, analogs & derivatives, therapeutic use)
• Fluorouracil (administration & dosage, analogs & derivatives, therapeutic use)
• Humans
• Male
• Middle Aged